The effect of Atorvastatin on chronic subdural hematoma status: A systematic review of drug therapy

Atorvastatin (ATO) with its chemical formula of (C33H35FN2O5) is one of the cholesterol-lowering drugs that can also reduce hematoma volume (HV). Considering the importance of pharmacological treatments in improving the patient condition, the aim of this study was to evaluate the ATO effect on chronic subdural hematoma (CSDH) status. In this systematic review (SR) study, all articles about the ATO effect on CSDH status were entered into a study, without time constraints, by two authors who were professional in SR articles. In the initial search, 176 articles were found, of which 73 articles were deleted due to duplicate records, and after further review and removal of unrelated articles, this number reduced to 11 articles, and systematic review data was reported with 11 articles. In all articles, radiological clinical findings were used to diagnose hematoma. In most of the reviewed articles, atorvastatin was effective in reducing subdural hemorrhage. The articles ranged from 2014 to 2021, the total sample size was 1278 patients and the follow-up period varied from 2 months to 4 years. Concerning the ATO effect in reducing HV status in CSDH patients, it is recommended to prescribe this drug to improve HV levels.